Quark will lead a lecture and present a poster on proprietary siRNA
targeting and delivery approaches
FREMONT, Calif., June 11 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced it will participate in the Cambridge Healthcare Institute's 9th Annual Beyond Genome Conference on June 8-11, 2008 at The Fairmont Hotel, San Francisco, CA.
Elena Feinstein, M.D., Ph.D., Chief Scientific Officer of Quark Pharmaceuticals will be presenting a lecture, "Temporary Inhibition of p53 of siRNA for Prevention of Acute Renal Failure: From Concept to Clinical Trials," at 1:50 PM (PT) on June 11, 2008.
Dr. Feinstein's lecture will discuss AKIi-5 and Quark's proprietary concept of temporarily inhibiting p53 as a systemic therapy to prevent the development of acute kidney injury (AKI) in response to ischemia-reperfusion stress. Following a successful preclinical program focused on safety, AKIi-5 is currently in Phase I clinical trials and represents the first ever systemic dosing of an siRNA in humans.
Dr. Swetlana Boldin-Adamsky, Project Director of Quark, will give a poster presentation, "Non-invasive Aerosol siRNA Delivery for the Treatment of Lung Tumors." The poster will discuss direct delivery of siRNA to the respiratory system by inhalation, a potential delivery method for various disorders, including lung cancer. Remarkably, the anti-cancer siRNA target utilized in these studies was discovered using Quark's proprietary BiFAR functional gene discovery platform. Targeting this gene for cancer treatment is covered by Quark's intellectual property.
Dr. Feinstein stated, "We are excited to participate in this year's
Beyond Genome conference. We have successfully administered the first siRNA
drug candidate systemically in humans with the initiation of our AKIi-5
Phase I clinical trial. This acc
|SOURCE Quark Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved